Diagnostic Utility Of Plasma LncRNA AFAP1-AS1 And SOX2OT In Non-small Cell Lung Cancer

ObjectiveLong non-coding RNA(lncRNA)AFAP1-AS1 and SOX2 OT have been found to play important roles in development and progression of tumors.The aim of this study is to asses diagnostic utility of plasma AFAP1-AS1 and SOX2 OT as biomarkers in non-small cell lung cancer(NSCLC).Method Blood samples of 48 NSCLC patients(NSCLC group)and 48 benign lung disease patients(control group)were collected,and plasma was separated within 1 hours following blood sample collection.The relative expression levels of AFAP1-AS1 and SOX2 OT were detected by real-time quantitative PCR.Potential relevancy between AFAP1-AS1 and SOX2 OT levels and clinical pathological characteristics in NSCLC patients were analyzed.The receiver operating characteristics(ROC)curve was constructed,and area under the ROC curve(AUC)was determined by statistical software to evaluate the diagnostic efficiency of the two lncRNAs as biomarkers for NSCLC.The sensitivity,specificity,positive predictive value,negative predictive value and accuracy of AFAP1-AS1 and SOX2 OT for the diagnosis of NSCLC were calculated and compared with carcinoembryonic antigen(CEA)..Result1.The levels of plasma lncRNA AFAP1-AS1 and lncRNA SOX2 OT were significantly increased in NSCLC patients compared to control group.2.The levels of plasma lncRNA AFAP1-AS1 and lncRNA SOX2 OT in NSCLC patients were correlated with histological types(P < 0.05),and the levels of the two lncRNAs in lung adenocarcinoma patients were higher than those in lung squamous cell carcinoma patients.3.The two plasma lncRNAs were used to distinguish NSCLC patients from control group with an area under ROC curve(AUC)of 0.875(95% CI 0.804~0.947;P < 0.001;sensitivity,87.4%;specificity,86.2%)for AFAP1-AS1 and 0.787(95% CI: 0.691-0.883;P < 0.001;sensitivity,73.0%;specificity,81.9%)for SOX2 OT,which were similar to serum CEA(0.836,95% CI 0.752–0.908;P < 0.001).4.The combination of lncRNA SOX2 OT and lncRNA AFAP1-AS1 obtained an AUC of0.901(95% CI: 0.832~0.968;P < 0.001;sensitivity,88.5%;specificity,90.7%),which was higher than those of AFAP1-AS1 or SOX2 OT alone.The two lncRNAs in combination with serum CEA further increased AUC for diagnosing NSCLC(0.914,95% CI: 0.849~0.978;P <0.001).ConclusionOur results signify that that combination of plasma lncRNA AFAP1-AS1 and lncRNA SOX2 OT had a higher diagnostic performance for NSCLC as compared with AFAP1-AS1 or SOX2 OT alone.Furthermore,combination of the two plasma lncRNAs and serum CEA which is classical tumor biomarker,could further improve diagnosis efficiency for NSCLC.Plasma lncRNA AFAP1-AS1 and SOX2 OT might be used as diagnostic biomarkers for NSCLC.